GSK plc (GSK)
NYSE: GSK · Real-Time Price · USD
37.32
-0.18 (-0.48%)
Apr 25, 2025, 12:02 PM EDT - Market open
GSK Employees
GSK plc had 68,629 employees as of December 31, 2024. The number of employees decreased by 1,583 or -2.25% compared to the previous year.
Employees
68,629
Change (1Y)
-1,583
Growth (1Y)
-2.25%
Revenue / Employee
$572,359
Profits / Employee
$46,973
Market Cap
75.13B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 68,629 | -1,583 | -2.25% |
Dec 31, 2023 | 70,212 | 812 | 1.17% |
Dec 31, 2022 | 69,400 | -20,696 | -22.97% |
Dec 31, 2021 | 90,096 | -3,970 | -4.22% |
Dec 31, 2020 | 94,066 | -5,371 | -5.40% |
Dec 31, 2019 | 99,437 | 3,947 | 4.13% |
Dec 31, 2018 | 95,490 | -2,972 | -3.02% |
Dec 31, 2017 | 98,462 | -838 | -0.84% |
Dec 31, 2016 | 99,300 | -1,955 | -1.93% |
Dec 31, 2015 | 101,255 | 3,334 | 3.40% |
Dec 31, 2014 | 97,921 | -1,530 | -1.54% |
Dec 31, 2013 | 99,451 | -37 | -0.04% |
Dec 31, 2012 | 99,488 | 2,099 | 2.16% |
Dec 31, 2011 | 97,389 | 928 | 0.96% |
Dec 31, 2010 | 96,461 | -3,452 | -3.46% |
Dec 31, 2009 | 99,913 | 910 | 0.92% |
Dec 31, 2008 | 99,003 | -4,480 | -4.33% |
Dec 31, 2007 | 103,483 | 788 | 0.77% |
Dec 31, 2006 | 102,695 | 1,967 | 1.95% |
Dec 31, 2005 | 100,728 | 709 | 0.71% |
Dec 31, 2004 | 100,019 | -900 | -0.89% |
Dec 31, 2003 | 100,919 | -3,580 | -3.43% |
Dec 31, 2002 | 104,499 | -2,971 | -2.76% |
Dec 31, 2001 | 107,470 | -47 | -0.04% |
Dec 31, 2000 | 107,517 | -1,524 | -1.40% |
Dec 31, 1999 | 109,041 | -7,780 | -6.66% |
Dec 31, 1998 | 116,821 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
GSK News
- 4 days ago - LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed - FXEmpire
- 8 days ago - UK approves combination therapies of GSK's blood cancer drug Blenrep - Reuters
- 8 days ago - Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease - GlobeNewsWire
- 8 days ago - AREXVY recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization Practices - Business Wire
- 8 days ago - GSK's 5-in-1 Meningococcal Vaccine PENMENVY Receives Positive Recommendation from US Advisory Committee on Immunization Practices - Business Wire
- 10 days ago - GSK in breach for misleading prescribing information on Omjjara, industry body says - Reuters
- 10 days ago - Trump says US pharma tariffs coming in not-too-distant future - Reuters
- 14 days ago - Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages - CNBC